Skip to main content

Two medicines, side by side

Clonidine vs carvedilol

Clonidine and carvedilol are both labeled for high blood pressure. Drugs@FDA records approvals of clonidine since 1974 and of carvedilol since 1995. Pharmacies paid $0.0241 per clonidine HCl 0.1 mg tablet and $0.0179 per carvedilol 6.25 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Clonidine's other strengths are brand-only: $1.53 per mL (Javadin 0.02 mg/mL solution). In FDA's classes, clonidine is a central alpha-2 adrenergic agonist and carvedilol an alpha-adrenergic blocker.

Check it at the source: the clonidine FDA label on DailyMed (effective March 30, 2026); the carvedilol FDA label on DailyMed (effective July 31, 2026).

Highlights of the clonidine record

Clonidine (Catapres) · label of March 30, 2026

Used for

From the label: indications

Clonidine hydrochloride tablets are indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents.

On the market

Earliest approval on file
September 3, 1974
Generic labelers
43 labelers
Pharmacy cost
$0.0241 per tablet

Supply and safety

Shortage
No current entry
Recalls
16

Highlights of the carvedilol record

Carvedilol (Coreg) · label of July 31, 2026

Used for

From the label: indications

INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]

On the market

Earliest approval on file
September 14, 1995
Generic labelers
41 labelers
Pharmacy cost
$0.0179 per tablet

Supply and safety

Shortage
No current entry
Recalls
22

Source: FDA drug labels via openFDA (Clonidine label of March 30, 2026, Carvedilol label of July 31, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)

How do clonidine and carvedilol differ on the record?

In FDA's classes, clonidine is a central alpha-2 adrenergic agonist and carvedilol an alpha-adrenergic blocker.

Half-life, in each label's words: Clonidine, “Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 …”; Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”

Generics: clonidine since 1986; carvedilol since 2007 (Drugs@FDA).

ClonidineCarvedilol
Labeled forHigh blood pressure, ADHD, PainHeart failure, High blood pressure
Pharmacologic classCentral alpha-2 Adrenergic Agonistalpha-Adrenergic Blocker, beta-Adrenergic Blocker
How it works (label)n/aCOREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency.
Half-life (label)Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours.Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
Earliest approval on file (Drugs@FDA)September 3, 1974September 14, 1995
First generic approvedJuly 1, 1986September 5, 2007
Generic labelers (NDC)43 labelers41 labelers
Pharmacy cost (NADAC, each one's most listed form; strengths differ)$0.0241 per tablet (Clonidine HCl 0.1 mg tablet)$0.0179 per tablet (Carvedilol 6.25 mg tablet)
12-month price change-3%-4%
Boxed warningNoNo
Shortage nowNo current entryNo current entry
Recalls recorded1622
FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used)57,116137,029
DEA schedulenonenone

Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)

What next?

Alternatives to clonidine
every medicine labeled for the same conditions